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1Background
We previously established the feasibility of Tumor-Infil-
trating Lymphocyte (TIL) cell therapy for unresectable
metastatic melanoma at our institution[1]. This involves
resection of tumor from patients for in vitro TIL genera-
tion. Upon satisfactory TIL growth, patients are rendered
lymphopenic with non-myeloablative chemotherapy and
receive adoptive cell therapy with TIL followed by high
dose Interleukin-2. We observed a 38% response rate, with
all responses ongoing to date (range, 34 to >54 months).
However, 35% of patients who underwent tumor harvest
dropped out prior to TIL transfer, primarily due to
progression of disease. This limitation may be addressed
by inclusion of additional treatment prior to TIL transfer.
Therefore, we combined vemurafenib with TIL therapy in
a clinical trial for patients with unresectable, BRAF V600-
mutated metastatic melanoma.
Methods
14 patients with unresectable, BRAF V600-mutated meta-
static melanoma were accrued to an Institutional Review
Board-approved trial (NCT01659151). All pts had >1 cm3
of soft tissue or nodal metastases resected for TIL genera-
tion leaving residual measurable disease. Vemurafenib
started the day after TIL harvest, was stopped prior to TIL
therapy, and then resumed after recovery from TIL ther-
apy. Clinical responses after TIL transfer were evaluated
by RECIST 1.1 criteria.
Results
Thirteen of 14 (93%) accrued patients received a median
of 5.1e10 TIL (9e9 – 8.6e10 cells). One patient was not
treated due to inadequate TIL growth. No patient dropped
out due to disease progression before receiving TIL. Of 12
evaluable patients, there were 5 responders (42% - 1 com-
plete, 4 partial responses) and 7 non-responders (58% - 2
stable disease, 5 progressive disease). Median progression-
free survival was not reached at a median follow-up of 364
days (range 104 – 910 days). There were no treatment-
related deaths.
Conclusions
The combination of vemurafenib with adoptive TIL ther-
apy for unresectable metastatic melanoma is feasible and
has the potential to reduce disease progression prior to
TIL transfer. This approach serves as a model for future
efforts to combine TIL with newer therapies including
inhibitors of BRAF/MEK, PD-1/PD-L1 blocking antibo-
dies, and other emerging immune checkpoint inhibitors.
Authors’ details
1H. Lee Moffitt Cancer Center, Tampa, FL, USA. 2H. Lee Moffitt Cancer Center
& Research Institute, Tampa, FL, USA.
Published: 4 November 2015
Reference
1. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, et al:
Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after
lymphopenia induction for metastatic melanoma. J Immunother
35(8):615-620.
doi:10.1186/2051-1426-3-S2-P49
Cite this article as: Sarnaik et al.: Clinical results of combined
vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic
melanoma. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P49.
Sarnaik et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P49
http://www.immunotherapyofcancer.org/content/3/S2/P49
